Treace Medical Concepts, Inc. (TMCI) stock
TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/3016% below fair value
$5.27−0.07 (-1.31%)
Close on Nov 13, 2026Market cap $342.73MP/E –Yield –
Treace Medical Concepts ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Treace Medical Concepts's ebitda for the twelve months ending Sep 30, 2026 was -$41.95M. For fiscal 2025 it was -$43.53M. The highest annual figure on record is $2.07M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$43.53M | – |
| FY2024 | Dec 31, 2024 | -$47.27M | – |
| FY2023 | Dec 31, 2023 | -$46.08M | – |
| FY2022 | Dec 31, 2022 | -$32.71M | – |
| FY2021 | Dec 31, 2021 | -$15.83M | -866.3% |
| FY2020 | Dec 31, 2020 | $2.07M | – |
| FY2019 | Dec 31, 2019 | -$2.74M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$9.50M | – |
| Q2 FY2026 | Jun 30, 2026 | -$13.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.11M | -253.2% |
| Q3 FY2025 | Sep 30, 2025 | -$12.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.12M | – |
| Q4 FY2024 | Dec 31, 2024 | $2.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.98M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.76M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.32M | -238.5% |
| Q3 FY2021 | Sep 30, 2021 | -$5.26M | -2319.4% |
| Q2 FY2021 | Jun 30, 2021 | -$3.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.29M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.84M | – |
| Q3 FY2020 | Sep 30, 2020 | $237.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$895.00K | – |
See a number that looks wrong?